08/06/2026 Zai Lab secures China NMPA approval for TIVDAK®, the first ADC for recurrent/metastatic cervical cancer Merck & Gilead halt Phase 3 KEYNOTE-D46/EVOKE-03 trial as Trodelvy + Keytruda fails to show statistically significant survival benefit in first-line PD-L1–high NSCLC Zai Lab secures China NMPA approval for TIVDAK®, the first ADC for recurrent/metastatic cervical cancer (Ref) China’s NMPA approved TIVDAK® (tisotumab vedotin) for adult patients with recurrent or me

Highlights from the Committee for Medicinal Products for Human Use (CHMP) January 2025 Meeting are out! Here are the positive...